These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

833 related items for PubMed ID: 19460829

  • 1. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R.
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [Abstract] [Full Text] [Related]

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group.
    Circ Cardiovasc Qual Outcomes; 2009 Nov 16; 2(6):616-23. PubMed ID: 20031900
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
    Cardiovasc J Afr; 2008 Nov 16; 19(6):332-4, discussion 335. PubMed ID: 19104734
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM, Friedewald VE, Davidson MH, Willerson JT, Roberts WC.
    Am J Cardiol; 2009 May 15; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009 May 15; 20(3):211. PubMed ID: 19575096
    [No Abstract] [Full Text] [Related]

  • 11. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ.
    Am J Cardiovasc Drugs; 2010 May 15; 10(6):383-400. PubMed ID: 21090831
    [Abstract] [Full Text] [Related]

  • 12. A tale of three labels: translating the JUPITER trial data into regulatory claims.
    Ridker PM.
    Clin Trials; 2011 Aug 15; 8(4):417-22. PubMed ID: 21835857
    [Abstract] [Full Text] [Related]

  • 13. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA.
    Future Cardiol; 2009 May 15; 5(3):231-6. PubMed ID: 19656039
    [Abstract] [Full Text] [Related]

  • 14. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
    Spatz ES, Canavan ME, Desai MM.
    Circ Cardiovasc Qual Outcomes; 2009 Jan 15; 2(1):41-8. PubMed ID: 20031811
    [Abstract] [Full Text] [Related]

  • 15. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group.
    Am J Cardiol; 2007 Dec 01; 100(11):1659-64. PubMed ID: 18036365
    [Abstract] [Full Text] [Related]

  • 16. Rosuvastatin for cardiovascular prevention: too many uncertainties.
    Prescrire Int; 2009 Aug 01; 18(102):176. PubMed ID: 19746571
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED, Blumenthal RS.
    J Am Coll Cardiol; 2009 Mar 17; 53(11):931-5. PubMed ID: 19281922
    [Abstract] [Full Text] [Related]

  • 18. [The JUPITER study: critical review of final results].
    Urbinati S, Romanazzi S, Gambetti S.
    G Ital Cardiol (Rome); 2009 Dec 17; 10(11-12 Suppl 3):28S-32S. PubMed ID: 21298859
    [Abstract] [Full Text] [Related]

  • 19. Extreme all-cause mortality in JUPITER requires reexamination of vital records.
    Serebruany VL.
    Cardiology; 2011 Dec 17; 120(2):84-8. PubMed ID: 22142620
    [Abstract] [Full Text] [Related]

  • 20. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
    Scheen AJ.
    Rev Med Liege; 2008 Dec 17; 63(12):749-53. PubMed ID: 19180837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.